Furthermore, our study showed that selective inhibition of HDAC10 increases the sensitivity of Sézary cells to the pro-apoptotic compound Camptothecin (CPT), even though the treatment with HDAC10i alone represented the relatively low potential of CTCL treatment due to low cytotoxicity. This evidence concerns the gene HDAC10 and primary cutaneous T-cell non-Hodgkin lymphoma.